<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-79901</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Differences in the use of tigecycline between ICU patients and non-ICU patients</dc:title>
<dc:description xml:lang="en">Background. Tigecycline is a new broad spectrumantibiotic that is predominantly used for the treatment ofsevere infections both in critically ill patients admittedto the ICU and in non-ICU patients with less severe clinicalconditions.Objetive. To assess differences in the use of tigecyclinebetween ICU patients and non-ICU patients treatedwith this antibiotics.Materials and methods. Retrospective, cohort, observationalstudy in which cases were defined as patientswho received one or more doses of tigecycline over thefirst 18 months after approval of the drug in a generalhospital. Clinical characteristics, indications, route of administration,clinical response, tolerability and outcomewere recorded in the groups of ICU and non-ICU patients.Descriptive data and results of the comparison ofboth cohorts are presented.Results. A total of 103 were included in the study, 34(33%) of which received tigecycline during their stay inthe ICU. ICU patients compared to non-ICU patients hada higher SAPS II score on admission (39.0 ± 11.8 vs 26.3± 8.0, p &lt; 0.001) and at the time of starting tigecyclinetreatment (42.2 ± 12.6 vs 25.6 ± 8.2, p &lt; 0.001), weretreated with antibiotics for more days (21.4 ± 30.6 vs13.6 ± 30.5 days, p &lt; 0.012) and received a greater numberof antibiotic agents concomitantly (85.3% vs 47.8%, p &lt; 0.001), presented a higher selection of emerging bacterialflora (41.2% vs 15.9%, p = 0.005), particularlyPseudomonas aeruginosa (20.6% vs 2.9%, p = 0.006),higher rate of clinical failure (58.8% vs 21.7%, p &lt;0.001), longer hospitalization (51.2 ± 39.4 vs 28.7 ±26.3 days, p &lt; 0.001) and higher overall mortality rate(50% vs 14.5%, p &lt; 0.001) and infection-attributed mortality(20.6% vs 7.2%, p = 0.047)(AU)</dc:description>
<dc:creator>Luque, S</dc:creator>
<dc:creator>Álvarez Lerma, F</dc:creator>
<dc:creator>Conde-Estévez, D</dc:creator>
<dc:creator>Rodríguez, J. A</dc:creator>
<dc:creator>Blanco, L</dc:creator>
<dc:creator>Grau, S</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Tigeciclina es un nuevo antibiótico de amplio espectro quese utiliza predominantemente para el tratamiento deinfecciones graves tanto en pacientes críticos, ingresados enUCI, como en pacientes menos graves.Objetivo. Analizar las diferencias en la utilización detigeciclina dependiendo de la ubicación de los pacientes en UCIo fuera de UCI.Material y método. Estudio observacional, retrospectivo,de cohortes en el que se define como caso los pacientes quehan utilizado una o más dosis de tigeciclina a lo largo de los 18primeros meses de su aprobación en un hospital general. Secomparan las características de los pacientes, indicaciones,formas de empleo del antibiótico, respuesta clínica,tolerabilidad y evolución de los pacientes dependiendo de suingreso en UCI cuando utilizaron tigeciclina Los datos sepresentan de forma descriptiva y mediante la comparación devariables entre las dos cohortes.Resultados. Se han incluido 103 pacientes de los que 34(33,0%) recibieron tigeciclina durante su estancia en UCI. Lospacientes ingresados en UCI tuvieron mayor SAPS II al ingresoen el hospital (39,0 ± 11,8 vs. 26,3 ± 8,0; p&lt;0,001) y al inicio deltratamiento con tigeciclina (42,2 ± 12,6 vs. 25.6 ± 8,2;p=0,001), utilizaron antibióticos de forma previa durante másdías (21,4 ± 30,6 vs. 13,6 ± 30,5; p&lt;0,012) y mas antibióticos deforma concomitante (85,3% vs. 47,8%; p&lt;0,001), presentaronmayor selección de flora emergente (41,2% vs. 15,9%;p=0,005), en especial P. aeruginosa (20,6% vs. 2,9%; p=0,006),mayor fracaso clínico (58,8% vs. 21,7%; p&lt;0,001) y seasociaron con mayor estancia hospitalaria (51,2 ± 39,4 vs. 28,7± 26,3 días; p&lt;0,001) y mayor mortalidad cruda (50,0% vs.14,5%; p&lt;0,001) y atribuida a la infección (20,6% vs. 7,2%;p=0,047)...(AU)</dc:description>
<dc:source>Rev Esp Quimioter;23(2): 63-71, jun.2010. tab</dc:source>
<dc:identifier>ibc-79901</dc:identifier>
<dc:title xml:lang="es">Diferencias en el uso de tigeciclina entre pacientes críticos y no críticos</dc:title>
<dc:subject>^d28621</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9099^s22073</dc:subject>
<dc:subject>^d3439^s22048</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d7530^s22049</dc:subject>
<dc:subject>^d9099^s22044</dc:subject>
<dc:subject>^d7530^s22048</dc:subject>
<dc:subject>^d9099^s22078</dc:subject>
<dc:subject>^d3439^s22045</dc:subject>
<dc:subject>^d9099^s22079</dc:subject>
<dc:subject>^d9099^s22003</dc:subject>
<dc:subject>^d8079^s22083</dc:subject>
<dc:subject>^d911^s22078</dc:subject>
<dc:subject>^d911^s22002</dc:subject>
<dc:subject>^d8079^s22066</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d13195</dc:subject>
<dc:type>article</dc:type>
<dc:date>201006</dc:date>
</metadata>
</record>
</ibecs-document>
